DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair, With death on the horizon, nothing will not stop me except God................DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 25Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK GENERICS at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution

Monday 29 December 2014

(±)-Methyl 2-[hydroxy(2-nitrophenyl)methyl]prop-2-enoate


1H NMR (500 MHz, CDCl3):  
δ 7.94 (dd, J 1.2/8.2 Hz, 1H), 
7.78 (d, 1H, J 7.9 Hz), 
7.61-7.67 (m, 1H), 
7.41-7.48 (m, 1H), 
6.36 (s, 1H), 
6.20 (s, 1H), 
5.72 (s, 1H), 
3.73 (s, 3H), 
3.08 (s, 1H, OH);





13C NMR (125 MHz, CDCl3):  
δ 166.3, 
148.2, 
140.7, 
136.0, 
133.4, 
128.8, 
128.6, 
126.4, 
124.5, 
67.6, 
52.1;



(±)-Methyl 2-[hydroxy(2-nitrophenyl)methyl]prop-2-enoate (3): 92% yield, pale yellow oil; IR (film) νmax/cm-1: 3469, 1716, 1630, 1528, 1352;  

1H NMR (500 MHz, CDCl3): δ 7.94 (dd, J 1.2/8.2 Hz, 1H), 7.78 (d, 1H, J 7.9 Hz), 7.61-7.67 (m, 1H), 7.41-7.48 (m, 1H), 6.36 (s, 1H), 6.20 (s, 1H), 5.72 (s, 1H), 3.73 (s, 3H), 3.08 (s, 1H, OH);

13C NMR (125 MHz, CDCl3): δ 166.3, 148.2, 140.7, 136.0, 133.4, 128.8, 128.6, 126.4, 124.5, 67.6, 52.1; 

HRMS (ESI TOF) 

Calcd. for C11H11NO5[M + Na+]: 260.0529. Found: 260.0530.




J. Braz. Chem. Soc. vol.22 no.8 São Paulo Aug. 2011

http://dx.doi.org/10.1590/S0103-50532011000800022


http://www.scielo.br/scielo.php?pid=S0103-50532011000800022&script=sci_arttext 


 your cock will teach you nmr







DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE


Join me on Linkedin

View Anthony Melvin Crasto Ph.D's profile on LinkedIn

Join me on Facebook FACEBOOK
Join me on twitterFollow amcrasto on Twitter     
Join me on google plus Googleplus

 amcrasto@gmail.com


No comments:

Post a Comment